Page last updated: 2024-08-24

nelfinavir and Leukemia

nelfinavir has been researched along with Leukemia in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bader, J; Berset, C; Berthod, G; Driessen, C; Hawle, H; Hess, D; Hitz, F; Huitema, A; Joerger, M; Kraus, M; Mey, UJ; Overkleeft, HS; Pabst, T; Rosing, H; Sessa, C; von Moos, R; Xyrafas, A	1
Brüning, A; Friese, K; Gingelmaier, A; Rahmeh, M	1

Trials

1 trial(s) available for nelfinavir and Leukemia

Article	Year
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). Haematologica, 2016, Volume: 101, Issue:3 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; HIV Protease Inhibitors; Humans; Leukemia; Leukocytes, Mononuclear; Lymphoma; Male; Middle Aged; Multiple Myeloma; Nelfinavir; Proteasome Endopeptidase Complex; Treatment Outcome; Unfolded Protein Response	2016

Article

Year

Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).

Haematologica, 2016, Volume: 101, Issue:3

Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; HIV Protease Inhibitors; Humans; Leukemia; Leukocytes, Mononuclear; Lymphoma; Male; Middle Aged; Multiple Myeloma; Nelfinavir; Proteasome Endopeptidase Complex; Treatment Outcome; Unfolded Protein Response

2016

Other Studies

1 other study(ies) available for nelfinavir and Leukemia

Article	Year
The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization. Molecular cancer, 2010, Jan-27, Volume: 9 Topics: Apoptosis; Benzenesulfonates; Bone Marrow Cells; Caspase 8; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cyclin B; Dose-Response Relationship, Drug; Down-Regulation; Drug Screening Assays, Antitumor; Enzyme Activation; Gene Expression Regulation, Leukemic; Humans; Leukemia; Membrane Potential, Mitochondrial; Mitochondria; Mitochondrial Membranes; Myeloid Cell Leukemia Sequence 1 Protein; Nelfinavir; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; Up-Regulation	2010

Article

Year

The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization.

Molecular cancer, 2010, Jan-27, Volume: 9

Topics: Apoptosis; Benzenesulfonates; Bone Marrow Cells; Caspase 8; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cyclin B; Dose-Response Relationship, Drug; Down-Regulation; Drug Screening Assays, Antitumor; Enzyme Activation; Gene Expression Regulation, Leukemic; Humans; Leukemia; Membrane Potential, Mitochondrial; Mitochondria; Mitochondrial Membranes; Myeloid Cell Leukemia Sequence 1 Protein; Nelfinavir; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; Up-Regulation

2010